IL158817A0 - Epf receptor assays, compounds and therapeutic compositions - Google Patents

Epf receptor assays, compounds and therapeutic compositions

Info

Publication number
IL158817A0
IL158817A0 IL15881702A IL15881702A IL158817A0 IL 158817 A0 IL158817 A0 IL 158817A0 IL 15881702 A IL15881702 A IL 15881702A IL 15881702 A IL15881702 A IL 15881702A IL 158817 A0 IL158817 A0 IL 158817A0
Authority
IL
Israel
Prior art keywords
epf
assays
compounds
test compound
therapeutic compositions
Prior art date
Application number
IL15881702A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL158817A0 publication Critical patent/IL158817A0/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pathology (AREA)
  • Reproductive Health (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
IL15881702A 2001-06-27 2002-06-26 Epf receptor assays, compounds and therapeutic compositions IL158817A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01202474 2001-06-27
PCT/EP2002/007263 WO2003005036A2 (en) 2001-06-27 2002-06-26 Epf receptor assays, compounds and therapeutic compositions

Publications (1)

Publication Number Publication Date
IL158817A0 true IL158817A0 (en) 2004-05-12

Family

ID=8180549

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15881702A IL158817A0 (en) 2001-06-27 2002-06-26 Epf receptor assays, compounds and therapeutic compositions
IL158817A IL158817A (en) 2001-06-27 2003-11-11 Tests for FPE receptor, compounds and medical preparations

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL158817A IL158817A (en) 2001-06-27 2003-11-11 Tests for FPE receptor, compounds and medical preparations

Country Status (17)

Country Link
US (2) US20040235722A1 (xx)
EP (1) EP1399744B1 (xx)
JP (1) JP4326326B2 (xx)
KR (2) KR100977824B1 (xx)
CN (1) CN100406891C (xx)
AT (1) ATE397218T1 (xx)
AU (1) AU2002317013B2 (xx)
CA (1) CA2450502C (xx)
DE (1) DE60226867D1 (xx)
DK (1) DK1399744T3 (xx)
ES (1) ES2307767T3 (xx)
HK (1) HK1070694A1 (xx)
IL (2) IL158817A0 (xx)
NO (1) NO341778B1 (xx)
NZ (1) NZ529714A (xx)
WO (1) WO2003005036A2 (xx)
ZA (1) ZA200309823B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1340979A3 (en) * 2002-02-27 2004-02-04 Pfizer Limited Neuropeptide receptor and uses thereof
CA2526847C (en) 2003-06-20 2011-01-25 Ambit Biosciences Corporation Assay and kits for detecting protein binding
DK1937723T3 (en) 2005-08-31 2014-02-24 Invion Ltd Modified chaperonin 10
CN101514335B (zh) * 2008-02-22 2013-04-17 中国科学院生物物理研究所 流感病毒聚合酶亚基pa的表达纯化及pa氨基端及pa羧基端与pb1氨基端多肽复合体的晶体结构
CN102015757B (zh) * 2008-04-11 2015-12-02 悉生物有限公司 修饰的Cpn10以及PRR信号

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2177179C (en) * 1993-11-30 2006-10-17 Halle Morton Antagonists to chaperonin 10
US5989804A (en) * 1994-07-08 1999-11-23 New England Medical Center Hospitals, Inc. E6 binding proteins
SE9704836D0 (sv) * 1997-12-22 1997-12-22 Astra Pharma Inc Novel receptor
JP2002502036A (ja) * 1998-02-02 2002-01-22 コンセプト ダイアグノスティクス， インコーポレイテッド 受胎動物を検出する方法および装置
JP2004500039A (ja) * 1999-09-16 2004-01-08 ソルベイ・フアーマシユーチカルズ・ベー・ブイ ヒトｇ−タンパク質共役型受容体
EP1242448A2 (en) * 1999-11-17 2002-09-25 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human g protein-coupled receptors

Also Published As

Publication number Publication date
EP1399744B1 (en) 2008-05-28
WO2003005036A3 (en) 2003-10-16
ATE397218T1 (de) 2008-06-15
ZA200309823B (en) 2005-05-25
ES2307767T3 (es) 2008-12-01
CA2450502A1 (en) 2003-01-16
WO2003005036A2 (en) 2003-01-16
IL158817A (en) 2012-01-31
KR100977824B1 (ko) 2010-08-25
HK1070694A1 (en) 2005-06-24
JP2005503543A (ja) 2005-02-03
US7402563B2 (en) 2008-07-22
CN100406891C (zh) 2008-07-30
CA2450502C (en) 2017-10-31
US20060160145A1 (en) 2006-07-20
DK1399744T3 (da) 2008-09-22
DE60226867D1 (de) 2008-07-10
NZ529714A (en) 2008-04-30
US20040235722A1 (en) 2004-11-25
KR20090111346A (ko) 2009-10-26
EP1399744A2 (en) 2004-03-24
JP4326326B2 (ja) 2009-09-02
AU2002317013B2 (en) 2007-11-01
NO341778B1 (no) 2018-01-15
KR100971270B1 (ko) 2010-07-20
NO20035771L (no) 2004-02-26
CN1541335A (zh) 2004-10-27
KR20040010644A (ko) 2004-01-31

Similar Documents

Publication Publication Date Title
JP2006502416A5 (xx)
DK1421389T3 (da) Neurofibrilmarkører
CA2358938A1 (en) Methods for assessing, improving, or maintaining urogenital health in postmenopausal women
EP1708745A4 (en) ANTIBODIES FOR ONCOGEN STRAINS OF HPV AND METHODS OF USE
IL209509A0 (en) Preimplantation factor peptide
HK1070694A1 (en) Identification of a compound capable of binding to hdrr or capable of modulating hdrr activity using a epf receptor, and isolation of hdrr
EA200200949A1 (ru) Метаболиты агониста/антагониста эстрогена
ZA200807766B (en) Inhibition of GASC1
ATE441642T1 (de) Hydantoin derivate mit affinität für somatostatin rezeptoren
Chansel et al. Characterization of [3H] losartan receptors in isolated rat glomeruli
BR0308890A (pt) Composto
DK1095275T3 (da) Endogen, konstitutivt aktiverede G-protein-koblede orphan-receptorer
EP1582870A4 (en) IMMUNOASSAY PROCEDURE AND KIT TO USE THEREOF
WO2003101176A8 (en) Method, composition and kit for antigenic binding of norwalk-like viruses
WO2002044368A1 (fr) Nouvelles proteines du recepteur couple a la proteine g et leurs adn
WO2003089615A3 (en) Antiviral inhibitions of capsid proteins
WO2002075273A3 (en) Screening, diagnostic and/or dosage method and device of an agonist and/or antagonist for a calcium-coupled receptor
WO2006023211A3 (en) Antigens targeted by pathogenic ai4 t cells in type 1 diabetes and uses thereof
ATE408144T1 (de) Assays
AU2003237702A1 (en) Method for identifying agonists or antagonists for the g-protein coupled mas-like 1 receptor
Matsubara et al. Evidence for the AT1 subtype of the angiotensin II receptor in the rat submandibular gland
WO2001068866A3 (en) Estrogen-regulated unconventional myosin-related protein: compositions and methods of use